{
    "2021-07-12": [
        [
            {
                "time": "2023-10-05",
                "original_text": "Prothena sells ATTR amyloidosis portfolio to Novo Nordisk for up to $1.2 billion",
                "features": {
                    "keywords": [
                        "Prothena",
                        "ATTR",
                        "amyloidosis",
                        "Novo Nordisk",
                        "$1.2 billion"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "healthcare",
                        "biotech"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2023-10-05",
                "original_text": "Novo Nordisk To Buy Prothena's ATTR Amyloidosis Program For Up To $1.2B",
                "features": {
                    "keywords": [
                        "Novo Nordisk",
                        "Prothena",
                        "ATTR",
                        "Amyloidosis",
                        "$1.2B"
                    ],
                    "sentiment_score": 0.85,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2023-10-05",
                "original_text": "Novo Nordisk A/S â€“ Share repurchase programme",
                "features": {
                    "keywords": [
                        "Novo Nordisk",
                        "share repurchase",
                        "programme"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "finance",
                        "corporate actions"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2023-10-05",
                "original_text": "Prothena sells amyloidosis portfolio to Novo Nordisk for up to $1.2 billion",
                "features": {
                    "keywords": [
                        "Prothena",
                        "amyloidosis",
                        "Novo Nordisk",
                        "$1.2 billion"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "healthcare",
                        "biotech"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2023-10-05",
                "original_text": "Novo Nordisk to buy Prothena's heart drug in deal worth up to $1.2 billion",
                "features": {
                    "keywords": [
                        "Novo Nordisk",
                        "Prothena",
                        "heart drug",
                        "$1.2 billion"
                    ],
                    "sentiment_score": 0.85,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2023-10-05",
                "original_text": "Novo Nordisk to buy Prothena's heart drug in deal worth up to $1.2 bln",
                "features": {
                    "keywords": [
                        "Novo Nordisk",
                        "Prothena",
                        "heart drug",
                        "$1.2 bln"
                    ],
                    "sentiment_score": 0.85,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            }
        ]
    ]
}